This HTML5 document contains 36 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
dbohttp://dbpedia.org/ontology/
foafhttp://xmlns.com/foaf/0.1/
n10https://global.dbpedia.org/id/
dbthttp://dbpedia.org/resource/Template:
rdfshttp://www.w3.org/2000/01/rdf-schema#
dbpedia-fahttp://fa.dbpedia.org/resource/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
wikipedia-enhttp://en.wikipedia.org/wiki/
dbchttp://dbpedia.org/resource/Category:
dbphttp://dbpedia.org/property/
provhttp://www.w3.org/ns/prov#
xsdhhttp://www.w3.org/2001/XMLSchema#
wikidatahttp://www.wikidata.org/entity/
dbrhttp://dbpedia.org/resource/

Statements

Subject Item
dbr:Vaccine-associated_enhanced_respiratory_disease
rdfs:label
Vaccine-associated enhanced respiratory disease
rdfs:comment
Vaccine-associated enhanced respiratory disease (VAERD), or simply enhanced respiratory disease (ERD), refers to an adverse event where an exacerbated course of respiratory disease occurs with higher incidence in the vaccinated population in comparison with the control group. It is one of the barriers against vaccine development and can lead to its failure. Immunologically, VAERD is characterized with an exaggerated Th2 response and eosinophilic pulmonary infiltrations. It is thought to arise as a result of antibody-mediated complement activation followed by weak neutralization.
dcterms:subject
dbc:Vaccination dbc:Drug-induced_diseases
dbo:wikiPageID
66893619
dbo:wikiPageRevisionID
1113477615
dbo:wikiPageWikiLink
dbr:COVID-19_vaccines dbr:Coronavirus dbr:Tozinameran dbc:Vaccination dbr:Infiltration_(medical) dbr:SARS-CoV dbr:SARS-CoV-2 dbr:Neutralization_(immunology) dbr:Antibody-mediated_complement_deposition dbr:Moderna_vaccine dbr:Respiratory_syncytial_virus dbc:Drug-induced_diseases dbr:Monitoring_(medicine) dbr:Course_(medicine) dbr:Middle_East_Respiratory_Syndrome dbr:Phase_III_clinical_trials dbr:Incidence_(epidemiology) dbr:Exacerbation dbr:Control_group dbr:Th2 dbr:Influenza dbr:Eosinophilic
owl:sameAs
n10:FwdWS dbpedia-fa:تشدید_بیماری_تنفسی_در_اثر_واکسن wikidata:Q105883426
dbp:wikiPageUsesTemplate
dbt:Short_description
dbo:abstract
Vaccine-associated enhanced respiratory disease (VAERD), or simply enhanced respiratory disease (ERD), refers to an adverse event where an exacerbated course of respiratory disease occurs with higher incidence in the vaccinated population in comparison with the control group. It is one of the barriers against vaccine development and can lead to its failure. Immunologically, VAERD is characterized with an exaggerated Th2 response and eosinophilic pulmonary infiltrations. It is thought to arise as a result of antibody-mediated complement activation followed by weak neutralization. Historical instances of the phenomenon were seen in vaccine candidates for respiratory syncytial virus, SARS-CoV, Middle East Respiratory Syndrome (MERS), as well as some Influenza strains. During the efforts to develop COVID-19 vaccines, whose target, SARS-CoV2, belongs to the same viral subfamily as SARS-CoV and MERS, concerns were raised about the possibility of exhibiting VAERD. Despite being monitored, the effect wasn't shown in phase III clinical trials for both Tozinameran and the Moderna vaccine.
prov:wasDerivedFrom
wikipedia-en:Vaccine-associated_enhanced_respiratory_disease?oldid=1113477615&ns=0
dbo:wikiPageLength
5028
foaf:isPrimaryTopicOf
wikipedia-en:Vaccine-associated_enhanced_respiratory_disease